In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

被引：37
作者：
Jansen, W. T. A. [1 ]
Verel, A. [1 ]
Verhoef, J. [1 ]
Milatovic, D. [1 ]
机构：
[1] Univ Med Ctr, NL-3584 CX Utrecht, Netherlands
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 09期
关键词：
D O I：
10.1128/AAC.00100-07
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC50 and MIC90) were both 0.25 mu g/ml, irrespective of methicillin resistance. MIC50 and MIC90 were 0.25 and 0.5 mu g/ml for vancomycin-susceptible enterococci and 1 and 2 mu g/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by <= 0.12 mu g/ml.
引用
收藏
页码：3420 / 3424
页数：5
相关论文
共 11 条
  • [1] Barrett John F, 2005, Curr Opin Investig Drugs, V6, P781
  • [2] *CLIN LAB STAND I\, 2005, M100S15
  • [3] In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
    Goldstein, EJC
    Citron, DM
    Merriam, CV
    Warren, YA
    Tyrrell, KL
    Fernandez, HT
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2149 - 2152
  • [4] Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
    Higgins, DL
    Chang, R
    Debabov, DV
    Leung, J
    Wu, T
    Krause, KA
    Sandvik, E
    Hubbard, JM
    Kaniga, K
    Schmidt, DE
    Gao, QF
    Cass, RT
    Karr, DE
    Benton, BM
    Humphrey, PP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 1127 - 1134
  • [5] Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria
    King, A
    Phillips, I
    Kaniga, K
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) : 797 - 803
  • [6] Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus
    Leuthner, Kimberly D.
    Cheung, Chrissy M.
    Rybak, Michael J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) : 338 - 343
  • [7] In vitro activity of TD-6424 against Staphylococcus aureus
    Pace, JL
    Krause, K
    Johnston, D
    Debabov, D
    Wu, T
    Farrington, L
    Lane, C
    Higgins, DL
    Christensen, B
    Judice, JK
    Kaniga, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3602 - 3604
  • [8] Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
    Shaw, JP
    Seroogy, J
    Kaniga, K
    Higgins, DL
    Kitt, M
    Barriere, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) : 195 - 201
  • [9] Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria
    Stryjewski, ME
    O'Riordan, WD
    Lau, WK
    Pien, FD
    Dunbar, LM
    Vallee, M
    Fowler, VG
    Chu, VH
    Spencer, E
    Barriere, SL
    Kitt, MM
    Cabell, CH
    Corey, GR
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1601 - 1607
  • [10] Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria:: FAST 2 study
    Stryjewski, ME
    Chu, VH
    O'Riordan, WD
    Warren, BL
    Dunbar, LM
    Young, DA
    Vallée, M
    Fowler, VG
    Morganroth, J
    Barriere, SL
    Kitt, MM
    Corey, GR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 862 - 867
12